Polysubstance abuse of alcohol and nicotine has been overlooked in our understanding of the neurobiology of addiction and especially in the development of novel therapeutics for its treatment. Estimates show that as many as 92% of people with alcohol use disorders also smoke tobacco. The health risks associated with both excessive alcohol consumption and tobacco smoking create an urgent biomedical need for the discovery of effective cessation treatments, as opposed to current approaches that attempt to independently treat each abused agent. The lack of treatment approaches for alcohol and nicotine abuse/dependence mirrors a similar lack of research in the neurobiology of polysubstance abuse. This review discusses three critical needs in medications development for alcohol and nicotine co-abuse: (1) the need for a better understanding of the clinical condition (i.e. alcohol and nicotine polysubstance abuse), (2) the need to better understand how these drugs interact in order to identify new targets for therapeutic development and (3) the need for animal models that better mimic this human condition. Current and emerging treatments available for the cessation of each drug and their mechanisms of action are discussed within this context followed by what is known about the pharmacological interactions of alcohol and nicotine. Much has been and will continue to be gained from studying comorbid alcohol and nicotine exposure.
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Introduction: prevalence and onset of alcohol, nicotine, and their concurrent use
Alcohol remains the most commonly used drug of abuse in the world, accounting for nearly 6% of global deaths annually (WHO, 2014) with millions more engaging in abusive drinking that has additional health, legal and social consequences (SAMHSA, 2014) . Alcohol use disorders (AUDs), or "alcoholism", are major public health problems as 13.9% of the U.S. population currently meets DSM-V diagnostic criteria for an AUD (Grant et al., 2015) . Within this group, 50-92% also smoke tobacco (Miller and Gold, 1998; Falk et al., 2006; De Leon et al., 2007) , which results in alcohol and nicotine abuse as the largest group of polysubstance abusers. Despite these striking numbers, preclinical research on this comorbid condition is relatively understudied, as investigators have focused primarily on understanding the effects of each of the drugs individually. Recently, this critical oversight has begun to be remedied through new NIH funding opportunities that already have served to increase the rate of discovery in alcohol and nicotine polysubstance abuse. As the 50%-92% incidence values show, comorbid alcohol and nicotine exposure is the human condition for the majority of people with an AUD.
Excessive alcohol use produces a great burden to society; it accounts for 2.3 million years of potential life lost and an estimated $223.5 billion in economic costs per year (Kanny et al., 2013) . Approximately 57% of Americans aged 21 and over have consumed alcohol in the last month (SAMHSA, 2014) while 18% of the adult population are binge drinkers (Kanny et al., 2013) . Binge drinking is defined by the National Institute on Alcohol Abuse and Alcoholism as a pattern of drinking that results in blood alcohol concentrations above the legal limit of 0.08 g/dL, through drinking 4+ drinks for women and 5+ drinks for men within 2 h. Although binge drinking is not necessarily synonymous with alcohol abuse, it is a risky pattern of consumption related to alcohol use problems. Tobacco use, on the other hand, is the leading cause of preventable death and accounts for approximately 20% of deaths per year (U.S. Department of Health and Human Services, 2014) . Nevertheless, 18% of adults over 18 years of age use tobacco products (Agaku et al., Progress in Neuro-Psychopharmacology & Biological Psychiatry 65 (2016) 269-287 Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AUD, alcohol use disorder; FDA, Food and Drug Administration; GABA A R, γ-aminobutyric acid receptor; NAc, nucleus accumbens; nAChRs, nicotinic acetylcholine receptors; NMDA, N-methyl-D-aspartate; P rat, alcohol-preferring rat; SSRI, selective serotonin reuptake inhibitor; VTA, ventral tegmental area.
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